A study of Oral CR845 in non-dialysis chronic kidney disease (CKD) associated pruritus population.

Trial Profile

A study of Oral CR845 in non-dialysis chronic kidney disease (CKD) associated pruritus population.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Oct 2017 According to a Cara Therapeutics media release, first patient has been dosed in the study.
    • 25 Oct 2017 Status changed from planning to recruiting, according to a Cara Therapeutics media release.
    • 03 Aug 2017 According to a Cara Therapeutics media release, the company expects to initiate this trial in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top